先天性心脏病儿童使用呋塞米与骨折风险增加相关
本研究基于2008-2014年德克萨斯州医疗补助数据库开展回顾性队列研究,纳入年龄<12岁、诊断为先天性心脏病、心肌病或心力衰竭的患儿。结果显示,呋塞米治疗(即使依从性不佳)与骨折风险增加相关,依从组骨折发生率9.1%,非依从组7.2%,均高于未用药组的5.0%(P < .001)。
要点
- 呋塞米依从组骨折风险较未用药组升高(OR 1.9, 95%CI 1.17-2.98)。
- 呋塞米非依从组骨折风险亦升高(OR 1.5, 95%CI 1.10-2.14)。
- 依从组骨折风险在Cox模型中仍显著升高(HR 1.6, 95%CI 1.00-2.42)。
核心结论
- 呋塞米治疗,即使非持续给药,与先天性心脏病儿童骨折风险增加相关。
研究设计与样本
- 回顾性队列研究,数据来自2008-2014年德克萨斯州医疗补助数据库,纳入年龄<12岁、诊断为先天性心脏病、心肌病或心力衰竭的患儿。
主要发现
- 匹配后共3912例患者:呋塞米依从组254例,非依从组724例,未用药组2934例。
- 骨折发生率依从组9.1%(23/254),非依从组7.2%(52/724),未用药组5.0%(148/2934),三组比较P < .001。
- 逻辑回归显示依从组骨折OR 1.9(95%CI 1.17-2.98; P = .009),非依从组OR 1.5(95%CI 1.10-2.14; P = .01)。
- Cox比例风险模型中依从组骨折风险显著高于未用药组(HR 1.6; 95%CI 1.00-2.42; P = .04)。
关键数值与推荐
- 呋塞米依从组定义:药物持有率≥70%;非依从组:药物持有率<70%。
- 倾向性评分匹配用于将未用药组与呋塞米用药组匹配。
临床怎么用
- 对先天性心脏病患儿使用呋塞米时,应关注骨折风险,尤其在高依从用药患者中。
局限性
- 回顾性队列设计可能受混杂因素影响;原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the association of furosemide therapy with the incidence of bone fractures in children with congenital heart disease. STUDY DESIGN: We conducted a retrospective cohort study with data extracted from the 2008-2014 Texas Medicaid databases. Pediatric patients aged <12 years diagnosed with congenital heart disease, cardiomyopathy, or heart failure were included. Patients taking furosemide were categorized into a furosemide-adherent group (medication possession ratio of ≥70%), and a furosemide-nonadherent group (medication possession ratio of <70%). A third group of patients was matched to the furosemide user groups by using propensity score matching. A multivariate logistic regression and Cox proportional hazard model with a Kaplan-Meier plot (time-to-fracture) were used to compare the 3 groups, controlling for baseline demographics and clinical characteristics. RESULTS: After matching, 3912 patients (furosemide adherent, n = 254; furosemide nonadherent, n = 724; no furosemide, n = 2934) were identified. The incidence of fractures was highest for the furosemide-adherent group (9.1%; 23 of 254), followed by the furosemide-nonadherent group (7.2%; 52 of 724), which were both higher than for patients who did not receive furosemide (5.0%; 148 of 2934) (P < .001). Using logistic regression, both furosemide groups were more likely to have fractures than the no furosemide group: furosemide-adherent OR of 1.9 (95% CI, 1.17-2.98; P = .009); furosemide nonadherent OR of 1.5 (95% CI, 1.10-2.14; P = .01). In the Cox proportional hazard model, the risk of fractures for the furosemide-adherent group was significantly higher compared with the no furosemide group (HR, 1.6; 95% CI, 1.00-2.42; P = .04). CONCLUSIONS: Furosemide therapy, even with nonconsistent dosing, was associated with an increased risk of bone fractures in children with congenital heart disease.
引用
- Heo JH, Rascati KL, Lopez KN, et al. Increased Fracture Risk with Furosemide Use in Children with Congenital Heart Disease. J Pediatr. 2018. PMID: 29753543. doi:10.1016/j.jpeds.2018.03.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。